nodes	percent_of_prediction	percent_of_DWPC	metapath
Drospirenone—BCHE—Cisplatin—testicular cancer	0.225	0.396	CbGbCtD
Drospirenone—PTGS2—Cisplatin—testicular cancer	0.173	0.305	CbGbCtD
Drospirenone—PTGS2—Etoposide—testicular cancer	0.17	0.299	CbGbCtD
Drospirenone—PGR—corpus luteum—testicular cancer	0.0774	0.259	CbGeAlD
Drospirenone—AR—scrotum—testicular cancer	0.0672	0.225	CbGeAlD
Drospirenone—AR—seminiferous tubule of testis—testicular cancer	0.0523	0.175	CbGeAlD
Drospirenone—AR—semen—testicular cancer	0.0289	0.0968	CbGeAlD
Drospirenone—PGR—Ovarian Infertility Genes—DAZL—testicular cancer	0.00952	0.447	CbGpPWpGaD
Drospirenone—NR3C2—seminal vesicle—testicular cancer	0.00827	0.0277	CbGeAlD
Drospirenone—AR—seminal vesicle—testicular cancer	0.00613	0.0205	CbGeAlD
Drospirenone—BCHE—seminal vesicle—testicular cancer	0.00499	0.0167	CbGeAlD
Drospirenone—NR3C2—female gonad—testicular cancer	0.00486	0.0163	CbGeAlD
Drospirenone—PGR—female gonad—testicular cancer	0.00452	0.0151	CbGeAlD
Drospirenone—Thromboembolic event—Methotrexate—testicular cancer	0.00451	0.0401	CcSEcCtD
Drospirenone—AR—gonad—testicular cancer	0.00443	0.0148	CbGeAlD
Drospirenone—NR3C2—testis—testicular cancer	0.00431	0.0144	CbGeAlD
Drospirenone—PTGS2—embryo—testicular cancer	0.00409	0.0137	CbGeAlD
Drospirenone—PGR—testis—testicular cancer	0.00401	0.0134	CbGeAlD
Drospirenone—Venous thromboembolism—Epirubicin—testicular cancer	0.00387	0.0344	CcSEcCtD
Drospirenone—NR3C2—Preimplantation Embryo—DNMT3L—testicular cancer	0.00387	0.182	CbGpPWpGaD
Drospirenone—PTGS2—seminal vesicle—testicular cancer	0.00384	0.0129	CbGeAlD
Drospirenone—AR—female gonad—testicular cancer	0.0036	0.0121	CbGeAlD
Drospirenone—Venous thromboembolism—Doxorubicin—testicular cancer	0.00358	0.0318	CcSEcCtD
Drospirenone—AR—testis—testicular cancer	0.00319	0.0107	CbGeAlD
Drospirenone—NR3C2—lymph node—testicular cancer	0.00312	0.0105	CbGeAlD
Drospirenone—PGR—lymph node—testicular cancer	0.0029	0.00972	CbGeAlD
Drospirenone—Cerebrovascular accident—Vinblastine—testicular cancer	0.00264	0.0234	CcSEcCtD
Drospirenone—Loss of libido—Methotrexate—testicular cancer	0.00263	0.0234	CcSEcCtD
Drospirenone—BCHE—testis—testicular cancer	0.0026	0.0087	CbGeAlD
Drospirenone—AR—lymph node—testicular cancer	0.00231	0.00775	CbGeAlD
Drospirenone—PTGS2—female gonad—testicular cancer	0.00226	0.00755	CbGeAlD
Drospirenone—Embolism venous—Epirubicin—testicular cancer	0.00225	0.02	CcSEcCtD
Drospirenone—Cerebrovascular accident—Bleomycin—testicular cancer	0.00223	0.0198	CcSEcCtD
Drospirenone—Embolism venous—Doxorubicin—testicular cancer	0.00209	0.0185	CcSEcCtD
Drospirenone—Depression—Vinblastine—testicular cancer	0.00199	0.0177	CcSEcCtD
Drospirenone—Acute coronary syndrome—Vinblastine—testicular cancer	0.00196	0.0175	CcSEcCtD
Drospirenone—Myocardial infarction—Vinblastine—testicular cancer	0.00195	0.0174	CcSEcCtD
Drospirenone—Embolism—Methotrexate—testicular cancer	0.00189	0.0168	CcSEcCtD
Drospirenone—BCHE—lymph node—testicular cancer	0.00188	0.0063	CbGeAlD
Drospirenone—Erythema multiforme—Chlorambucil—testicular cancer	0.00184	0.0164	CcSEcCtD
Drospirenone—Haemoglobin—Vinblastine—testicular cancer	0.0018	0.016	CcSEcCtD
Drospirenone—Haemorrhage—Vinblastine—testicular cancer	0.00179	0.0159	CcSEcCtD
Drospirenone—Embolism—Epirubicin—testicular cancer	0.00177	0.0158	CcSEcCtD
Drospirenone—Breast disorder—Ifosfamide—testicular cancer	0.00169	0.015	CcSEcCtD
Drospirenone—Acute coronary syndrome—Bleomycin—testicular cancer	0.00166	0.0147	CcSEcCtD
Drospirenone—Myocardial infarction—Bleomycin—testicular cancer	0.00165	0.0147	CcSEcCtD
Drospirenone—Cerebrovascular accident—Cisplatin—testicular cancer	0.00164	0.0146	CcSEcCtD
Drospirenone—Embolism—Doxorubicin—testicular cancer	0.00164	0.0146	CcSEcCtD
Drospirenone—Thrombosis—Epirubicin—testicular cancer	0.00161	0.0143	CcSEcCtD
Drospirenone—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.00154	0.0723	CbGpPWpGaD
Drospirenone—Haemoglobin—Bleomycin—testicular cancer	0.00152	0.0135	CcSEcCtD
Drospirenone—Haemorrhage—Bleomycin—testicular cancer	0.00151	0.0134	CcSEcCtD
Drospirenone—Thrombosis—Doxorubicin—testicular cancer	0.00149	0.0132	CcSEcCtD
Drospirenone—Breast disorder—Cisplatin—testicular cancer	0.00145	0.0129	CcSEcCtD
Drospirenone—PTGS2—lymph node—testicular cancer	0.00145	0.00486	CbGeAlD
Drospirenone—Acute coronary syndrome—Ifosfamide—testicular cancer	0.00142	0.0126	CcSEcCtD
Drospirenone—Myocardial infarction—Ifosfamide—testicular cancer	0.00141	0.0125	CcSEcCtD
Drospirenone—Erythema multiforme—Dactinomycin—testicular cancer	0.00133	0.0118	CcSEcCtD
Drospirenone—Breast pain—Epirubicin—testicular cancer	0.0013	0.0116	CcSEcCtD
Drospirenone—Haemoglobin—Ifosfamide—testicular cancer	0.0013	0.0115	CcSEcCtD
Drospirenone—Haemorrhage—Ifosfamide—testicular cancer	0.00129	0.0115	CcSEcCtD
Drospirenone—Acute coronary syndrome—Cisplatin—testicular cancer	0.00122	0.0109	CcSEcCtD
Drospirenone—Erythema multiforme—Ifosfamide—testicular cancer	0.00122	0.0108	CcSEcCtD
Drospirenone—Myocardial infarction—Cisplatin—testicular cancer	0.00121	0.0108	CcSEcCtD
Drospirenone—Breast pain—Doxorubicin—testicular cancer	0.00121	0.0107	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.0012	0.0106	CcSEcCtD
Drospirenone—Angiopathy—Ifosfamide—testicular cancer	0.00117	0.0104	CcSEcCtD
Drospirenone—Mental disorder—Ifosfamide—testicular cancer	0.00113	0.01	CcSEcCtD
Drospirenone—Acute coronary syndrome—Etoposide—testicular cancer	0.00112	0.00995	CcSEcCtD
Drospirenone—Myocardial infarction—Etoposide—testicular cancer	0.00111	0.00989	CcSEcCtD
Drospirenone—Erythema multiforme—Etoposide—testicular cancer	0.000964	0.00857	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00095	0.00844	CcSEcCtD
Drospirenone—Angiopathy—Etoposide—testicular cancer	0.000925	0.00822	CcSEcCtD
Drospirenone—Cerebrovascular accident—Methotrexate—testicular cancer	0.0009	0.008	CcSEcCtD
Drospirenone—Nervous system disorder—Ifosfamide—testicular cancer	0.000899	0.00799	CcSEcCtD
Drospirenone—Skin disorder—Ifosfamide—testicular cancer	0.00089	0.00792	CcSEcCtD
Drospirenone—Cerebrovascular accident—Epirubicin—testicular cancer	0.000843	0.00749	CcSEcCtD
Drospirenone—Mood swings—Methotrexate—testicular cancer	0.000836	0.00743	CcSEcCtD
Drospirenone—Nausea—Chlorambucil—testicular cancer	0.000823	0.00732	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.000819	0.00728	CcSEcCtD
Drospirenone—Affect lability—Epirubicin—testicular cancer	0.000813	0.00723	CcSEcCtD
Drospirenone—Migraine—Epirubicin—testicular cancer	0.000813	0.00723	CcSEcCtD
Drospirenone—Breast disorder—Methotrexate—testicular cancer	0.000797	0.00709	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.000791	0.00704	CcSEcCtD
Drospirenone—Mood swings—Epirubicin—testicular cancer	0.000782	0.00695	CcSEcCtD
Drospirenone—Cerebrovascular accident—Doxorubicin—testicular cancer	0.00078	0.00693	CcSEcCtD
Drospirenone—Nervous system disorder—Cisplatin—testicular cancer	0.000775	0.00689	CcSEcCtD
Drospirenone—Skin disorder—Cisplatin—testicular cancer	0.000768	0.00682	CcSEcCtD
Drospirenone—Nausea—Vinblastine—testicular cancer	0.000754	0.00671	CcSEcCtD
Drospirenone—Migraine—Doxorubicin—testicular cancer	0.000752	0.00669	CcSEcCtD
Drospirenone—Affect lability—Doxorubicin—testicular cancer	0.000752	0.00669	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00075	0.00667	CcSEcCtD
Drospirenone—Breast disorder—Epirubicin—testicular cancer	0.000746	0.00663	CcSEcCtD
Drospirenone—Mood swings—Doxorubicin—testicular cancer	0.000724	0.00643	CcSEcCtD
Drospirenone—Skin disorder—Etoposide—testicular cancer	0.000703	0.00625	CcSEcCtD
Drospirenone—Breast disorder—Doxorubicin—testicular cancer	0.00069	0.00614	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000682	0.00607	CcSEcCtD
Drospirenone—Depression—Methotrexate—testicular cancer	0.000678	0.00603	CcSEcCtD
Drospirenone—Nausea—Bleomycin—testicular cancer	0.000637	0.00566	CcSEcCtD
Drospirenone—Gastrointestinal disorder—Etoposide—testicular cancer	0.000625	0.00556	CcSEcCtD
Drospirenone—Haemoglobin—Methotrexate—testicular cancer	0.000613	0.00545	CcSEcCtD
Drospirenone—Haemorrhage—Methotrexate—testicular cancer	0.00061	0.00543	CcSEcCtD
Drospirenone—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000595	0.0279	CbGpPWpGaD
Drospirenone—Nausea—Dactinomycin—testicular cancer	0.000594	0.00528	CcSEcCtD
Drospirenone—Erythema multiforme—Methotrexate—testicular cancer	0.000577	0.00513	CcSEcCtD
Drospirenone—Haemoglobin—Epirubicin—testicular cancer	0.000574	0.0051	CcSEcCtD
Drospirenone—Haemorrhage—Epirubicin—testicular cancer	0.000571	0.00508	CcSEcCtD
Drospirenone—PTGS2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000556	0.0261	CbGpPWpGaD
Drospirenone—Angiopathy—Methotrexate—testicular cancer	0.000554	0.00492	CcSEcCtD
Drospirenone—Nausea—Ifosfamide—testicular cancer	0.000544	0.00484	CcSEcCtD
Drospirenone—Erythema multiforme—Epirubicin—testicular cancer	0.00054	0.0048	CcSEcCtD
Drospirenone—Mental disorder—Methotrexate—testicular cancer	0.000535	0.00475	CcSEcCtD
Drospirenone—Haemoglobin—Doxorubicin—testicular cancer	0.000531	0.00472	CcSEcCtD
Drospirenone—Haemorrhage—Doxorubicin—testicular cancer	0.000529	0.0047	CcSEcCtD
Drospirenone—Angiopathy—Epirubicin—testicular cancer	0.000518	0.00461	CcSEcCtD
Drospirenone—Mental disorder—Epirubicin—testicular cancer	0.0005	0.00445	CcSEcCtD
Drospirenone—Erythema multiforme—Doxorubicin—testicular cancer	0.0005	0.00444	CcSEcCtD
Drospirenone—Angiopathy—Doxorubicin—testicular cancer	0.00048	0.00426	CcSEcCtD
Drospirenone—Nausea—Cisplatin—testicular cancer	0.000469	0.00417	CcSEcCtD
Drospirenone—Mental disorder—Doxorubicin—testicular cancer	0.000463	0.00412	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000449	0.00399	CcSEcCtD
Drospirenone—Nausea—Etoposide—testicular cancer	0.00043	0.00382	CcSEcCtD
Drospirenone—Nervous system disorder—Methotrexate—testicular cancer	0.000425	0.00378	CcSEcCtD
Drospirenone—Skin disorder—Methotrexate—testicular cancer	0.000421	0.00374	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00042	0.00374	CcSEcCtD
Drospirenone—Nervous system disorder—Epirubicin—testicular cancer	0.000398	0.00354	CcSEcCtD
Drospirenone—Skin disorder—Epirubicin—testicular cancer	0.000394	0.0035	CcSEcCtD
Drospirenone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000389	0.00346	CcSEcCtD
Drospirenone—PTGS2—C-MYB transcription factor network—MAD1L1—testicular cancer	0.000385	0.0181	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000374	0.00333	CcSEcCtD
Drospirenone—Nervous system disorder—Doxorubicin—testicular cancer	0.000368	0.00327	CcSEcCtD
Drospirenone—Skin disorder—Doxorubicin—testicular cancer	0.000365	0.00324	CcSEcCtD
Drospirenone—NR3C2—Gene Expression—DNMT3L—testicular cancer	0.000356	0.0167	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—KITLG—testicular cancer	0.000351	0.0165	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Epirubicin—testicular cancer	0.00035	0.00311	CcSEcCtD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000331	0.0155	CbGpPWpGaD
Drospirenone—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000324	0.00288	CcSEcCtD
Drospirenone—AR—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.00029	0.0136	CbGpPWpGaD
Drospirenone—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	0.00027	0.0127	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—H2AFZ—testicular cancer	0.000268	0.0126	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—FGFR3—testicular cancer	0.000261	0.0122	CbGpPWpGaD
Drospirenone—Nausea—Methotrexate—testicular cancer	0.000258	0.00229	CcSEcCtD
Drospirenone—PTGS2—C-MYB transcription factor network—KITLG—testicular cancer	0.000247	0.0116	CbGpPWpGaD
Drospirenone—Nausea—Epirubicin—testicular cancer	0.000241	0.00214	CcSEcCtD
Drospirenone—AR—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000241	0.0113	CbGpPWpGaD
Drospirenone—PGR—Signaling by ERBB4—KIT—testicular cancer	0.000239	0.0112	CbGpPWpGaD
Drospirenone—Nausea—Doxorubicin—testicular cancer	0.000223	0.00198	CcSEcCtD
Drospirenone—PGR—Gene Expression—DNMT3L—testicular cancer	0.000217	0.0102	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00019	0.00894	CbGpPWpGaD
Drospirenone—PTGS2—C-MYB transcription factor network—KIT—testicular cancer	0.000169	0.00791	CbGpPWpGaD
Drospirenone—AR—Gene Expression—DNMT3L—testicular cancer	0.000165	0.00776	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—INSL3—testicular cancer	0.000154	0.00724	CbGpPWpGaD
Drospirenone—PTGS2—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.000138	0.00649	CbGpPWpGaD
Drospirenone—NR3C2—Gene Expression—H2AFZ—testicular cancer	0.000125	0.00586	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000116	0.00542	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.95e-05	0.00373	CbGpPWpGaD
Drospirenone—PGR—Gene Expression—H2AFZ—testicular cancer	7.6e-05	0.00357	CbGpPWpGaD
Drospirenone—AR—Gene Expression—H2AFZ—testicular cancer	5.79e-05	0.00272	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—HPGDS—testicular cancer	5.14e-05	0.00241	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—H2AFZ—testicular cancer	4.94e-05	0.00232	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—STK11—testicular cancer	4.91e-05	0.00231	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—KITLG—testicular cancer	4.54e-05	0.00213	CbGpPWpGaD
Drospirenone—BCHE—Metabolism of proteins—MMP2—testicular cancer	4.06e-05	0.0019	CbGpPWpGaD
Drospirenone—BCHE—Metabolism—STK11—testicular cancer	3.74e-05	0.00175	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—HPGDS—testicular cancer	3.54e-05	0.00166	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—FGFR3—testicular cancer	3.38e-05	0.00159	CbGpPWpGaD
Drospirenone—PGR—Signaling Pathways—KIT—testicular cancer	3.1e-05	0.00146	CbGpPWpGaD
Drospirenone—PTGS2—Disease—H2AFZ—testicular cancer	3.09e-05	0.00145	CbGpPWpGaD
Drospirenone—PTGS2—Disease—KITLG—testicular cancer	2.84e-05	0.00133	CbGpPWpGaD
Drospirenone—PTGS2—Metabolism—STK11—testicular cancer	2.57e-05	0.00121	CbGpPWpGaD
Drospirenone—PTGS2—Disease—FGFR3—testicular cancer	2.11e-05	0.000992	CbGpPWpGaD
Drospirenone—PTGS2—Disease—KIT—testicular cancer	1.94e-05	0.000911	CbGpPWpGaD
